DOCSLIB.ORG

Alpha-L-Iduronidase Transduced Mesenchymal Stem Cells As A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alpha-L-Iduronidase Transduced Mesenchymal Stem Cells As A ALPHA-L-IDURONIDASE TRANSDUCED MESENCHYMAL STEM CELLS AS A THERAPY FOR THE TREATMENT OF CNS DEGENERATION IN MUCOPOLYSACCHARIDOSIS TYPE I MICE Matilda Jackson BMSc, BSc (Hons) Matrix Biology Unit SA Pathology Thesis submitted for the degree of Doctor of Philosophy in Discipline of Genetics School of Molecular and Biomedical Sciences Faculty of Science The University of Adelaide Table of contents Abstract........................................................................................................... vii Declaration....................................................................................................... ix Acknowledgements ........................................................................................... x Abbreviations .................................................................................................. xi Chapter One: Introduction .............................................................................. 1 1.0 Overview .................................................................................................................... 2 1.1 The Mucopolysaccharidoses .................................................................................... 3 1.1.1 Mucopolysaccharidoses type I......................................................................................... 5 1.1.2 Central Nervous System (CNS) pathology ...................................................................... 7 1.1.3 Bone pathology ............................................................................................................... 9 1.2 Therapies ................................................................................................................. 10 1.2.1 Current therapies ........................................................................................................... 11 1.2.1.1 Mechanisms for enzyme targeting .......................................................................... 11 1.2.1.2 Bone marrow transplant ........................................................................................ 14 1.2.1.3 Enzyme replacement therapy.................................................................................. 16 1.2.2 Potential therapies ......................................................................................................... 17 1.2.2.1 Gene therapy .......................................................................................................... 17 1.2.2.2 Substrate deprivation therapy ................................................................................ 18 1.2.2.3 Stem cell therapy .................................................................................................... 19 1.3 Mesenchymal stem cells .......................................................................................... 20 1.3.1 Isolation and characterisation ........................................................................................ 23 1.3.2 MSCs for therapeutic use .............................................................................................. 24 1.3.3 Homing and immunomodulation ................................................................................... 26 1.3.4 Immunosuppression ...................................................................................................... 27 1.3.4.1 Cyclosporin mediated immunosuppression ............................................................ 28 1.4 MPS animal models ................................................................................................ 28 1.4.1 MPS I murine model ..................................................................................................... 29 1.5 Behaviour testing in rodents .................................................................................. 31 1.5.1 Inverted grid .................................................................................................................. 31 1.5.2 Rotarod .......................................................................................................................... 33 1.5.3 Open field ...................................................................................................................... 33 1.5.4 Water cross maze .......................................................................................................... 34 1.6 Hypothesis and Aims .............................................................................................. 35 1.6.1 Significance ................................................................................................................... 36 Chapter Two: Materials and Methods .......................................................... 37 2.2 In vitro experimentation ......................................................................................... 38 2.2.1 Cell line basal growth media ......................................................................................... 38 2.2.1.1 Cell line culture ...................................................................................................... 38 2.2.2 Determination of enzyme activity ................................................................................. 39 2.2.2.1 Sample collection ................................................................................................... 39 2.2.2.2 Fluorogenic substrates ........................................................................................... 39 2.2.2.3 Radio-labelled substrates ....................................................................................... 39 2.2.2.4 Bradford protein assay ........................................................................................... 40 2.2.3 Virus production ............................................................................................................ 40 2.2.3.1 Plasmid preparation .............................................................................................. 40 ii 2.2.3.1.1 pUC57-mmIdua purification ............................................................................. 40 2.2.3.1.2 pHIV-EF1αluciferase purification ........................................................................ 41 2.2.3.2 Vector and insert ligation ....................................................................................... 41 2.2.3.3 Transformation of sure E.coli cells ........................................................................ 41 2.2.3.4 Miniprep ................................................................................................................ 42 2.2.3.4.1 Restriction enzyme digest of plasmid .................................................................... 42 2.2.3.5 Midiprep ................................................................................................................ 43 2.2.3.5.1DNA sequencing .................................................................................................... 43 2.2.3.6 Gigaprep ................................................................................................................ 43 2.2.3.7 Virus preparation ................................................................................................... 43 2.2.3.8 Viral transfection ................................................................................................... 44 2.2.3.9 Transduction efficiency .......................................................................................... 45 2.2.4 Mannose-6-phosphate mediated cross correction .......................................................... 45 2.2.4.1 Over-expression of enzyme in hDP or hBM MSCs ................................................. 45 2.2.4.2 Cross-correction by addition of hDP or hBM derived enzyme ............................... 45 2.2.4.3 35SO4 incorporation .............................................................................................. 46 2.2.5 Stable β-D-glucuronidase transduction without splitting ............................................... 46 2.2.5.1 Stable β-glucuronidase transduction with continual splitting ................................ 47 2.2.5.2 Vector copy number per cell .................................................................................. 47 2.2.6 Stem cell differentiation ................................................................................................ 47 2.2.6.1 Osteogenic differentiation ...................................................................................... 47 2.2.6.1.1 Osteogenic quantification ..................................................................................... 48 2.2.6.2 Adipogenic differentiation ...................................................................................... 48 2.2.6.2.1 Adipogenic quantification .................................................................................... 48 2.2.6.3 Chondrogenic differentiation ................................................................................. 49 2.2.6.3.1 Chondrogenic quantification ................................................................................ 49 2.2.6.4 Neurogenic differentiation ..................................................................................... 50 2.2.6.4.1 Neurogenic quantification .................................................................................... 50 2.3 MPS I husbandry .................................................................................................... 50 2.3.1 MPS I genotyping.........................................................................................................
Load more

Recommended publications
  • Bacteria Belonging to Pseudomonas Typographi Sp. Nov. from the Bark Beetle Ips Typographus Have Genomic Potential to Aid in the Host Ecology
    insects Article Bacteria Belonging to Pseudomonas typographi sp. nov. from the Bark Beetle Ips typographus Have Genomic Potential to Aid in the Host Ecology Ezequiel Peral-Aranega 1,2 , Zaki Saati-Santamaría 1,2 , Miroslav Kolaˇrik 3,4, Raúl Rivas 1,2,5 and Paula García-Fraile 1,2,4,5,* 1 Microbiology and Genetics Department, University of Salamanca, 37007 Salamanca, Spain; [email protected] (E.P.-A.); [email protected] (Z.S.-S.); [email protected] (R.R.) 2 Spanish-Portuguese Institute for Agricultural Research (CIALE), 37185 Salamanca, Spain 3 Department of Botany, Faculty of Science, Charles University, Benátská 2, 128 01 Prague, Czech Republic; [email protected] 4 Laboratory of Fungal Genetics and Metabolism, Institute of Microbiology of the Academy of Sciences of the Czech Republic, 142 20 Prague, Czech Republic 5 Associated Research Unit of Plant-Microorganism Interaction, University of Salamanca-IRNASA-CSIC, 37008 Salamanca, Spain * Correspondence: [email protected] Received: 4 July 2020; Accepted: 1 September 2020; Published: 3 September 2020 Simple Summary: European Bark Beetle (Ips typographus) is a pest that affects dead and weakened spruce trees. Under certain environmental conditions, it has massive outbreaks, resulting in attacks of healthy trees, becoming a forest pest. It has been proposed that the bark beetle’s microbiome plays a key role in the insect’s ecology, providing nutrients, inhibiting pathogens, and degrading tree defense compounds, among other probable traits. During a study of bacterial associates from I. typographus, we isolated three strains identified as Pseudomonas from different beetle life stages. In this work, we aimed to reveal the taxonomic status of these bacterial strains and to sequence and annotate their genomes to mine possible traits related to a role within the bark beetle holobiont.
    [Show full text]
  • Epidemiology of Mucopolysaccharidoses Update
    diagnostics Review Epidemiology of Mucopolysaccharidoses Update Betul Celik 1,2 , Saori C. Tomatsu 2 , Shunji Tomatsu 1 and Shaukat A. Khan 1,* 1 Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA; [email protected] (B.C.); [email protected] (S.T.) 2 Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA; [email protected] * Correspondence: [email protected]; Tel.: +302-298-7335; Fax: +302-651-6888 Abstract: Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by a lysosomal enzyme deficiency or malfunction, which leads to the accumulation of glycosaminoglycans in tissues and organs. If not treated at an early stage, patients have various health problems, affecting their quality of life and life-span. Two therapeutic options for MPS are widely used in practice: enzyme replacement therapy and hematopoietic stem cell transplantation. However, early diagnosis of MPS is crucial, as treatment may be too late to reverse or ameliorate the disease progress. It has been noted that the prevalence of MPS and each subtype varies based on geographic regions and/or ethnic background. Each type of MPS is caused by a wide range of the mutational spectrum, mainly missense mutations. Some mutations were derived from the common founder effect. In the previous study, Khan et al. 2018 have reported the epidemiology of MPS from 22 countries and 16 regions. In this study, we aimed to update the prevalence of MPS across the world. We have collected and investigated 189 publications related to the prevalence of MPS via PubMed as of December 2020. In total, data from 33 countries and 23 regions were compiled and analyzed.
    [Show full text]
  • Uptake of -(L)-Iduronidase Produced by Retrovirally Transduced
    Gene Therapy (1997) 4, 63–75 1997 Stockton Press All rights reserved 0969-7128/97 $12.00 Uptake of a-(L)-iduronidase produced by retrovirally transduced fibroblasts into neuronal and glial cells in vitro K Stewart1, OA Brown1, AE Morelli1, LJ Fairbairn2, LS Lashford2,3, A Cooper4, CE Hatton4, TM Dexter2, MG Castro1 and PR Lowenstein1 1Molecular Medicine Unit, Department of Medicine, University of Manchester School of Medicine; 2CRC Department of Experimental Haematology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester; 3Academic Unit of Pediatric Oncology, Christie Hospital NHS Trust, Manchester; and 4Willink Biochemical Genetics Unit, Royal Manchester Children’s Hospital, Manchester, UK The uptake of recombinant a-(L)-iduronidase into glial and higher in actively dividing or immature brain cells. Conse- neuronal cells, produced by retrovirally transduced NIH3T3 quently, (1) neuronal metabolism ought to be capable of fibroblasts, was studied. We demonstrate that: (1) neuronal cross correction by enzyme provided by genetically engine- and glial cells take up a-(L)-iduronidase released into the ered and transplanted cells provided by bone marrow medium by retrovirally transduced fibroblasts expressing transplantation (BMT); (2) that BMT could have a more high levels of a-(L)-iduronidase; (2) both glial and neuronal beneficial effect on neurological function if performed as cells express the cation independent mannose-6-phos- early as possible; and (3) given that the uptake mechanism phate receptor responsible for lysosomal enzyme uptake; of glial cells has a higher capacity, it might be easier to and (3) uptake of the lysosomal enzyme can be blocked target diseases like the leukodystrophies in which lysoso- by excess free mannose-6-phosphate, but not glucose-6- mal enzymes are needed in glial cells, compared to dis- phosphate.
    [Show full text]
  • Functional Characterization of Carbohydrate-Active Enzymes from Marine Bacteria
    Functional characterization of carbohydrate-active enzymes from marine bacteria I n a u g u r a l d i s s e r t a t i o n zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) der Mathematisch-Naturwissenschaftlichen Fakultät der Universität Greifswald vorgelegt von Marcus Bäumgen Greifswald, 28.02.2020 Dekan: Prof. Dr. Werner Weitschies 1. Gutachter: Prof. Dr. Uwe T. Bornscheuer 2. Gutachter: Prof. Dr. Harry Brumer Tag der Promotion: 24.06.2020 II III Wissenschaft ist das Werkzeug, welches es uns ermöglicht, das große Puzzel der Natur und des Lebens zu lösen. IV Auch wenn wir den Weg des Wissens und der Weisheit niemals bis zum Ende beschreiten können, so ist doch jeder Schritt, den wir tun, ein Schritt in eine bessere Welt. V Content Abbreviations ..................................................................................................................... IX 1. Introduction ..................................................................................................................... 1 1.1 The marine carbon cycle .............................................................................................. 1 1.1.1 Algal blooms .......................................................................................................... 1 1.1.2 The marine carbohydrates ulvan and xylan ........................................................... 2 1.1.3 Marine polysaccharide utilization ........................................................................... 4 1.2 Carbohydrate-active enzymes
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,981,835 Austin-Phillips Et Al
    USOO598.1835A United States Patent (19) 11 Patent Number: 5,981,835 Austin-Phillips et al. (45) Date of Patent: Nov. 9, 1999 54) TRANSGENIC PLANTS AS AN Brown and Atanassov (1985), Role of genetic background in ALTERNATIVE SOURCE OF Somatic embryogenesis in Medicago. Plant Cell Tissue LIGNOCELLULOSC-DEGRADING Organ Culture 4:107-114. ENZYMES Carrer et al. (1993), Kanamycin resistance as a Selectable marker for plastid transformation in tobacco. Mol. Gen. 75 Inventors: Sandra Austin-Phillips; Richard R. Genet. 241:49-56. Burgess, both of Madison; Thomas L. Castillo et al. (1994), Rapid production of fertile transgenic German, Hollandale; Thomas plants of Rye. Bio/Technology 12:1366–1371. Ziegelhoffer, Madison, all of Wis. Comai et al. (1990), Novel and useful properties of a chimeric plant promoter combining CaMV 35S and MAS 73 Assignee: Wisconsin Alumni Research elements. Plant Mol. Biol. 15:373-381. Foundation, Madison, Wis. Coughlan, M.P. (1988), Staining Techniques for the Detec tion of the Individual Components of Cellulolytic Enzyme 21 Appl. No.: 08/883,495 Systems. Methods in Enzymology 160:135-144. de Castro Silva Filho et al. (1996), Mitochondrial and 22 Filed: Jun. 26, 1997 chloroplast targeting Sequences in tandem modify protein import specificity in plant organelles. Plant Mol. Biol. Related U.S. Application Data 30:769-78O. 60 Provisional application No. 60/028,718, Oct. 17, 1996. Divne et al. (1994), The three-dimensional crystal structure 51 Int. Cl. ............................. C12N 15/82; C12N 5/04; of the catalytic core of cellobiohydrolase I from Tricho AO1H 5/00 derma reesei. Science 265:524-528.
    [Show full text]
  • Enzyme Replacement Therapy Srx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment
    MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 06/15/2011 03/15/2017 10/04/2016 Policy Name Policy Number Enzyme Replacement Therapy SRx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures. Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.
    [Show full text]
  • Pompe Disease
    Substrate Localisation as a Therapeutic Option for Pompe Disease A thesis submitted to The University of Adelaide for the degree of DOCTOR OF PHILOSOPHY by Christopher Travis Turner, BBtech (Hons) Lysosomal Diseases Research Unit Department of Genetic Medicine Women’s & Children’s Hospital North Adelaide, South Australia, 5006 October 2013 Paediatrics Paediatrics and Reproductive Health The University of Adelaide 1 Table of Contents Abstract 7 Declaration of authenticity 9 Acknowledgments 10 Abbreviations 11 List of figures 15 List of tables 18 Chapter 1 – Introduction 19 1.1 The endosome-lysosome System 20 1.1.1 The endosome 20 1.1.2 The lysosome 25 1.1.3 Autophagosomes 28 1.2 Pompe disease 36 1.2.1 Incidence 37 1.2.2 Clinical manifestations 37 1.2.3 Genetics 39 1.2.4 Diagnosis 41 1.2.5 Lysosomal acid α-glucosidase (GAA) 42 1.2.6 Glycogen synthesis and metabolism 44 1.2.6.1 Glycogen synthesis 46 1.2.6.2 Glycogen catabolism 49 2 1.2.6.3 Autophagy and lysosomal degradation of glycogen 50 1.2.7 Glycogen accumulation in Pompe disease 52 1.2.8 Treatment of Pompe disease 54 1.2.8.1 Gene therapy 54 1.2.8.2 Chaperone therapy 55 1.2.8.3 Enzyme replacement therapy 56 1.3 Exocytosis 60 1.3.1 Ca2+-dependent exocytosis 62 1.3.2 Exocytic mechanism 64 1.3.3 All-or-none exocytosis 66 1.3.4 Cavicapture 66 1.3.5 The contribution of all-or-none exocytosis and cavicapture to the overall amount of exocytosis 67 1.3.6 Evidence for the exocytosis of glycogen in Pompe disease 68 1.4 Hypothesis and aims 70 Chapter 2 – Materials and Methods 71 2.1 Materials 72
    [Show full text]
  • Poster Session Abstracts
    Poster Session Abstracts Poster sessions will be in the Harbor Ballroom on: Tuesday, March 1 from 4:30‐6:30pm Wednesday, March 2 from 4:30‐6:00pm. No photos or videos are permitted of any oral or poster sessions. The only exception is at the official poster sessions if the author is present and gives permission. Any poster numbers not listed will not be presented as the author is unable to attend the conference. It is the policy of WORLDSymposium to publish all abstracts with the list of authors exactly as the abstract was submitted to WORLDSymposium. The first author of the submitted abstract will be listed as the presenting author on the Preliminary Program, Agenda, and Poster List. Poster # First Author Abstract Title 1 Magy Abdelwahab Long‐term follow up and sudden unexpected death in Gaucher disease type 3 in Egypt 2 Magy Abdelwahab Ocular abnormalities in Egyptian Gaucher disease patients 3 Walter Acosta Lectin‐mediated delivery of α‐L‐iduronidase: a novel approach for MPS I enzyme replacement therapy 4 Elma Aflaki iPSC‐derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism demonstrate the potential of a new glucocerebrosidase chaperone 5 Nicholas Agard Evolving improved therapeutic proteins for treating Fabry disease 6 Patricio Aguiar Prognostic model for hearing loss in Fabry disease 7 Patricio Aguiar Urinary type IV collagen: better than albuminuria to identify incipient Fabry nephropathy 8 Alia Ahmed Association of physical symptom score (PSS) with age and cognitive measures in attenuated mucopolysaccharidosis
    [Show full text]
  • Illinois Department of Public Health
    NEWBORN SCREENING OFFICE OF HEALTH PROMOTION 535 W. Jefferson St., 2nd Floor Springfield, IL 62761 Phone: 217-785-8101 Fax: 217-557-5396 Mucopolysaccharidosis Type I (MPS I) Disease (Hurler, Hurler-Scheie and Scheie Syndromes) Information for Physicians and Other Health Care Professionals Definition MPS I disease, also frequently referred to as Hurler syndrome, is an inherited, autosomal recessive lysosomal storage disorder caused by deficiency in the activity of the enzyme alpha-L-iduronidase. This enzyme is responsible for the breakdown of certain glycosaminoglycans (GAGs). Lysosomal accumulation of these GAG molecules results in cell, tissue and organ dysfunction. Clinical Symptoms MPS I is a multisystem disorder and presents in three types with a wide range of symptoms. The severe form, MPS I H, also known as Hurler syndrome, has more severe symptoms that usually start within the first year of life. Symptoms of MPS I may include mental retardation and developmental delays, short stature, stiff joints, speech and hearing impairment, heart and lung disease, enlarged liver and spleen, hernia, coarse facial features, hydrocephalus, spinal compression, pain and a shortened life span. The other subtypes of MPS I are MPS I H-S (Hurler-Scheie syndrome) and MPS I S (Scheie syndrome). Children with MPS I H-S and MPS I S may have normal intelligence with milder symptoms starting later in childhood. Newborn Screening and Definitive Diagnosis In Illinois, newborn screening for MPS I disease is performed by measuring alpha-L-iduronidase enzyme activity. If newborn screening results indicate abnormal activity of this enzyme, referral should be made to a metabolic disease specialist.
    [Show full text]
  • Alpha-L-Iduronidase Transduced Mesenchymal Stem Cells As A
    ALPHA-L-IDURONIDASE TRANSDUCED MESENCHYMAL STEM CELLS AS A THERAPY FOR THE TREATMENT OF CNS DEGENERATION IN MUCOPOLYSACCHARIDOSIS TYPE I MICE Matilda Jackson BMSc, BSc (Hons) Matrix Biology Unit SA Pathology Thesis submitted for the degree of Doctor of Philosophy in Discipline of Genetics School of Molecular and Biomedical Sciences Faculty of Science The University of Adelaide Table of contents Abstract........................................................................................................... vii Declaration....................................................................................................... ix Acknowledgements ........................................................................................... x Abbreviations .................................................................................................. xi Chapter One: Introduction .............................................................................. 1 1.0 Overview .................................................................................................................... 2 1.1 The Mucopolysaccharidoses .................................................................................... 3 1.1.1 Mucopolysaccharidoses type I......................................................................................... 5 1.1.2 Central Nervous System (CNS) pathology ...................................................................... 7 1.1.3 Bone pathology ..............................................................................................................
    [Show full text]
  • Toward Engineering the Mannose 6-Phosphate Elaboration Pathway in Plants for Enzyme Replacement Therapy of Lysosomal Storage Disorders
    Journal of Clinical Medicine Article Toward Engineering the Mannose 6-Phosphate Elaboration Pathway in Plants for Enzyme Replacement Therapy of Lysosomal Storage Disorders Ying Zeng 1, Xu He 1, Tatyana Danyukova 2, Sandra Pohl 2 and Allison R. Kermode 1,* 1 Department of Biological Sciences, Simon Fraser University, Burnaby, BC V5A1S6, Canada; [email protected] (Y.Z.); [email protected] (X.H.) 2 Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; [email protected] (T.D.); [email protected] (S.P.) * Correspondence: [email protected]; Tel.: +778-782-3982 Received: 16 October 2019; Accepted: 7 December 2019; Published: 12 December 2019 Abstract: Mucopolysaccharidosis (MPS) I is a severe lysosomal storage disease caused by α-L-iduronidase (IDUA) deficiency, which results in accumulation of non-degraded glycosaminoglycans in lysosomes. Costly enzyme replacement therapy (ERT) is the conventional treatment for MPS I. Toward producing a more cost-effective and safe alternative to the commercial mammalian cell-based production systems, we have produced recombinant human IDUA in seeds of an Arabidopsis mutant to generate the enzyme in a biologically active and non-immunogenic form containing predominantly high mannose N-linked glycans. Recombinant enzyme in ERT is generally thought to require a mannose 6-phosphate (M6P) targeting signal for endocytosis into patient cells and for intracellular delivery to the lysosome. Toward effecting in planta phosphorylation, the human M6P elaboration machinery was successfully co-expressed along with the recombinant human IDUA using a single multi-gene construct. Uptake studies using purified putative M6P-IDUA generated in planta on cultured MPS I primary fibroblasts indicated that the endocytosed recombinant lysosomal enzyme led to substantial reduction of glycosaminoglycans.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0165635 A1 Copenhaver Et Al
    US 2011 O165635A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0165635 A1 Copenhaver et al. (43) Pub. Date: Jul. 7, 2011 (54) METHODS AND MATERALS FOR Publication Classification PROCESSINGA FEEDSTOCK (51) Int. Cl. CI2P I 7/04 (2006.01) (75) Inventors: Gregory P. Copenhaver, Chapel CI2P I/00 (2006.01) Hill, NC (US); Daphne Preuss, CI2P 7/04 (2006.01) Chicago, IL (US); Jennifer Mach, CI2P 7/16 (2006.01) Chicago, IL (US) CI2P 7/06 (2006.01) CI2P 5/00 (2006.01) CI2P 5/02 (2006.01) (73) Assignee: CHROMATIN, INC., Chicago, IL CI2P3/00 (2006.01) (US) CI2P I/02 (2006.01) CI2N 5/10 (2006.01) (21) Appl. No.: 12/989,038 CI2N L/15 (2006.01) CI2N I/3 (2006.01) (52) U.S. Cl. ........... 435/126; 435/41; 435/157; 435/160; (22) PCT Fled: Apr. 21, 2009 435/161; 435/166; 435/167; 435/168; 435/171; 435/419,435/254.11: 435/257.2 (86) PCT NO.: PCT/US2O09/041260 (57) ABSTRACT S371 (c)(1), The present disclosure relates generally to methods for pro (2), (4) Date: Mar. 11, 2011 cessing a feedstock. Specifically, methods are provided for processing a feedstock by mixing the feedstock with an addi tive organism that comprises one or more transgenes coding Related U.S. Application Data for one or more enzymes. The expressed enzymes may be (60) Provisional application No. 61/046,705, filed on Apr. capable of breaking down cellulosic and lignocellulosic 21, 2008. materials and converting them to a biofuel.
    [Show full text]